IRVINE, Calif. and ZHUHAI, China, Oct. 24, 2011 /PRNewswire/ --Masimo (NASDAQ: MASI) and Biolight, a leading global manufacturer of electronic medical devices and patient monitors, today jointly announced both a worldwide technology licensing agreement and the launch of Masimo rainbow® SET Pulse CO-Oximetry technology in Biolight’s new generation of modular patient monitors. The agreement allows Biolight to incorporate the breakthrough noninvasive blood constituent measurement capabilities of Masimo rainbow SET into Biolight’s Anyview Series of modular monitors and the Measure-Through Motion and Low Perfusion pulse oximetry capabilities of Masimo SET across Biolight’s product line of multiparameter patient monitors - facilitating early detection and treatment of life-threatening conditions.
According to James Yan, Chairman General Manager, Professor Senior Engineering, R&D. “Our corporate mission is to provide innovative medical devices with superior performance and value. The integration of Masimo rainbow SET Pulse CO-Oximetry and Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry technologies is an example of our mission in action. Masimo’s innovative technologies and breakthrough noninvasive monitoring solutions provide clinicians with the ability to more rapidly and thoroughly assess a patient’s physiological status and make better clinical and treatment decisions.”
Integrating Masimo rainbow SET Pulse CO-Oximetry technology into Biolight’s Anyview Series of modular monitors will provide immediate and continuous access to additional clinical measurement data - enabling clinicians to detect and treat the early signs of hemodynamic instability, internal bleeding, and respiratory distress sooner. Masimo rainbow SET Pulse CO-Oximetry is a breakthrough technology platform revolutionizing patient monitoring by significantly expanding the ability to noninvasively measure and continuously track multiple blood constituents that previously required intermittent, invasive procedures, including: total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and perfusion index (PI), in addition to the ‘gold standard’ Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), and pulse rate (PR).
“The inclusion of Masimo technologies will allow us to optimize the design and manufacture of state-of-the-art patient monitors and provide our domestic and international customers with access to the latest in cutting-edge, noninvasive physiological measurements,” continued Yan. “As one of the first medical device manufacturers in China to incorporate Masimo’s rainbow SET technology, we expect our combined product offering will allow clinicians to advance the delivery of healthcare across all patient care settings.”
Incorporating Masimo’s core Signal Extraction Technology (SET) pulse Oximetry technology into Biolight’s non-modular “M” and “V” Series of patient monitors will also help clinicians more accurately measure a patient’s oxygenation during challenging conditions such as patient motion and low perfusion to facilitate better treatment decisions as clinically proven in over 100 independent studies. Utilizing patented signal processing technologies, including parallel engines and adaptive filters, Masimo SET delivers accurate and reliable measurements of a patient’s true oxygenation status when conventional pulse oximetry technologies don’treducing false alarms by over 95% (sensitivity) and expanding true alarm detection to over 97% (specificity).(1)
Rick Fishel, President of Worldwide OEM Business and Corporate Development at Masimo, stated, “Biolight is one of the first patient monitoring manufacturers in China to integrate Masimo rainbow SET Pulse CO-Oximetry technology. This “first-to-market” commitment in Biolight’s modular Anyview series of patient monitors provides Biolight customers with advanced physiological monitoring across a broad range of monitors which offer a unique combination of upgradeability and point-of-care flexibility.”
1 Shah N., Estanol L. “An Evaluation of Three New Generation Pulse Oximeters during Motion & Low Perfusion in Volunteers.”Anesthesiology 2006; 102: S-75.
To see a summary of all known clinical studies and abstracts on Masimo technologies, please visit: http://www.masimo.com/cpub/clinicals.htm.
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care - helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo’s rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com.
About Guangdong Biolight Meditech Co., Ltd.
Guangdong Biolight Meditech Co., Ltd. is a high-tech company located in Zhuhai, focusing on developing, producing and marketing medical instruments including patient monitoring systems, central monitoring systems, and electrocardiograph and digital colposcope systems. Founded in 1993, Biolight has successfully developed advanced medical electronic equipment in nearly 10 series and 40 types, including multi parameter patient monitors, central monitoring stations, and digital colposcope imaging systems. Biolight products have a considerable market share in China. We are also selling well in the international market and we have distributors in Asia, the Middle East, Europe and America. In 2003, Biolight built a new technology industrial park which covers 20,000sqm for developing and producing patient monitoring systems.
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that the superior performance of Masimo SET pulse oximetry and the clinical importance of the upgradeable Masimo rainbow® SET Pulse CO-Oximetry technology platform have contributed to the growth and adoption of Masimo technologies, risks related to our belief that Masimo technologies help hospitals to improve patient care and enhance patient safety initiatives , as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Media Contacts: | ||
Dana Banks | Thomas Lee | |
Masimo Corporation | Biolight Co., Ltd. | |
Phone: (949) 297-7348 | Phone: 0086-756-3399996 | |
Email: dbanks@masimo.com | Email: thomas@blt.com.cn | |
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.
SOURCE Masimo Corporation
